Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX) are starting a 24-week Phase III...

Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)